The mechanism of induction of cytotoxicity produced by anti-CD3 monoclonal antibody (MoAb) was studied in four patients with CD3+ large granular lymphocyte ( Both subsets mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity. Because of phenotypic and molecular features that suggest different cell origins, it has been proposed that these two subsets be recognized as discrete cell types: (1) natural killer (NK) cells, CD3 -LGL and (2) non-MHC-restricted cytotoxic T lymphocytes (CTL), CD3+
The mechanism of induction of cytotoxicity produced by anti-CD3 monoclonal antibody (MoAb) was studied in four patients with CD3+ large granular lymphocyte (LGL) leukemia. Anti Both subsets mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity. Because of phenotypic and molecular features that suggest different cell origins, it has been proposed that these two subsets be recognized as discrete cell types: (1) natural killer (NK) cells, CD3 -LGL and (2) non-MHC-restricted cytotoxic T lymphocytes (CTL), CD3+ LGL. ' LGL leukemia results from a chronic proliferation of either CD3-or CD3+ LGL, which may be associated with chronic ne~tropenia,~.~ cyclic neutropenia: or rheumatoid arthritis.*'.'. ' The phenotypic and molecular features of CD3 -and CD3+ leukemic LGL are similar to their normal co~nterparts~.~; therefore, these cells should be valuable for studying normal LGL differentiation and activation. Although the activation of normal NK cells has been well studied, there is little information concerning the activation of normal CD3 + LGL, since these cells constitute only 2% of peripheral blood mononuclear cells (PBMC).'.' Recent reports have documented a p75 non-Tuc interleukin-2 (IL-2)-binding peptide on normal and leukemic LGL that binds IL-2 with intermediate affinit~.~.'' Through this receptor, high doses of IL-2 serve as a signal for both proliferation and
We showed previously that anti-CD3 monoclonal antibody (MoAb) induces cytotoxicity but does not cause proliferation of CD3+ leukemic LGL." Using two-color immunofluorescent-activated cell sorting, we showed that the effect of anti-CD3 MoAb in inducing cytotoxicity was on leukemic LGL and not on normal T cells.'5 Therefore, it is likely that IL-2 and anti-CD3 MoAb provide different signals for activation of these LGL. In this study we examined the mechanism of CD3 + LGL activation at the cellular and molecular levels. Our results suggest that induction of cytotoxicity produced by treatment with anti-CD3 MoAb occurs through an IL-2-independent pathway.
MATERIALS AND METHODS
All patients met clinical criteria for diagnosis of LGL leukemia.I6 LGL counts varied from 5,000 to 9,00O/rL (normal, Cytotoxicity assay. PBMC were assessed for non-MHCrestricted cytotoxicity against K562 cell line using a 4-hour "Cr release assay, as described.Is In some experiments, MOLT-4 was also used as target. Lytic units were calculated as lytic units per lo6 cells for 30% killing of lo4 target cells. 19 Our previous study showed that maximum induction of cytotoxicity occurred at 48 hours; cytotoxicity declined at 72 hours, and at 96 hours, was only minimally elevated above backgro~nd.'~ Therefore, these experiments were performed at time 0 and at 4,8,24, and 48 hours after activation.
PBMC at a concentration of 1 x 106/mL were incubated for various times at 37OC in a 95% air/5% CO, humidified atmosphere with 1 PguglmL of anti-CD3 MoAb, as described." Our previous study using dose-response experiments showed that this was the optimum dose of anti-CD3 MoAb for induction of cytoto~icity.'~ Electron microscopy.
Target-cell binding assay.
Unactivated and activated PBMC were fixed in gluteraldehyde and examined as described.20
This assay was performed as described previously.2' In brief, untreated PBMC or PBMC treated with anti-CD3 MoAb were incubated with K562 at an effector: target ratio of 1:l for 30 minutes at 37OC, centrifuged at 130g for 5 minutes, and gently resuspended. The percent of target-effector conjugates was determined using light microscopy.
These studies were performed on unactivated and 48-hour activated PBMC from LGL leukemia patients, as described.22 Radiolabeled ('251) IL-2 was purchased from New England Nuclear (Newton, MA); purified recombinant IL-2 used as a cold competitor was a generous gift of Cetus Corp (Emeryville, CA). '251-labeled IL-2 receptor complexes were produced by covalently crosslinking '2'I-labeled IL-2 to unactivated and activated PBMC from these patients. Cells were incubated with 5 nmol/L '2'I-labeled IL-2, crosslinked with disuccinimdyl suberate, solubilized, and electrophoresed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described.22 For equilibrium binding analysis, serial dilutions of 1251-labeled IL-2 were incubated with 1 to 10 x 10' cells for 20 minutes, then cell-bound and free radioactivity was determined after separation by centrifugation through a mixture of 84% silicone oil and 16% paraffin oil, as previously described.22 To accurately quantitate ligand binding, especially on cells exposed to IL-2, any receptorbound IL-2 was dissociated by a 60-second exposure to RPMI containing 25 mmol/L sodium acetate, followed by three washes with cold RPMI medium. The number of binding sites per cell was determined by Scatchard analysis after subtraction of nonsaturable binding in the presence of a 150-fold excess of unlabeled IL-2. Supernatants from cultures of PBMC from LGL leukemia patients activated with anti-CD3 MoAb at 4-, 8-, 24-, and 48-hour time points were examined for evidence of IL-2 production. As a control for IL-2 production, supernatants from cultures of normal T cells activated with anti-CD3 MoAb and from cultures of highly purified normal LGL activated with y interferon (IFN) were also examined. Biological activity was measured on an IL-2-dependent mouse lymphocyte line, CTLL-2. Cells were seeded into 96-well, flat-bottom microtiter plates (Costar, Cambridge, MA) at a concentration of 2 x lo4 cells per well in 100 ~J L growth medium without IL-2. An equal volume of test or control medium was added to the cells in several dilutions. The cultures were then incubated an additional 18 hours. The cells were labeled with 50 pL of 'Hthymidine at 20 MCi/mL (specific activity of 6.7 Ci/mmol; New England Nuclear) for 6 hours. The cells in each well were then harvested onto filter paper. Results of counts per minute/2 x lo4 cells were used to calculate 50% of the maximum activity of a standard IL-2 preparation from a dose response curve by using a least-squares fit of a cubic polynomial. The recombinant IL-2 used to standardize the assay was the Interim Reference Standard of the Biologic Response Modifers Program of the National Cancer Institute. Units of IL-2 activity were defined as the reciprocal of the dilution factor required to give 50% maximum response in the above assay. The sensitivity of this assay is such that 1.5 U/mL of IL-2 can be detected.
RNA was extracted from PBMC in the presence of guanidinium isothiocyanate at time 0, and at 4, 
RESULTS
Induction of cytotoxicity. The kinetics of activation of cytotoxicity are shown in Table 1 . Induction of cytotoxicity was first detected in cells from patients 1 and 4 after 4 hours of activation, in patient 2 after 48 hours of activation, and in patient 3 after 24 hours of activation.
All four patients had CD3 + LGL leukemia, with 78% to 99% of PBMC reacting with anti-CD3. These cells were TCRaP + and TCRyG -. Unactivated cells from all four patients were Tac negative; after 48 hours of activation, only cells from patient 3 became Tac positive (72%). Figure 1 shows results of electron microscopic examination of unactivated versus activated cells from patient 1. A marked increase in Golgi complex, granule formation, and parallel tubular arrays was noted in activated cells. Similar results were obtained in the other patient examined.
Increased target cel.1 binding by effector cells from three of four patients was observed after anti-CD3 MoAb treatment (Table 2) .
Crosslinking studies using radiolabeled IL-2 showed that unactivated PBMC from patients 2 and 4 expressed only the p75 peptide, whereas PBMC from patient 3 expressed both p75 and p55 peptides, similar to activated normal T cells (Fig 2) . Additional bands of higher molecular weight observed in both patients 2 and 4 probably represent different glycosylated moieties of the p75 peptide rather than another IL-2 binding peptide. Scatchard analysis of equilibrium binding studies showed that the number of intermediate affinity p75 receptors per cell increased after activation (Table 3) .
In all four patients, there was no evidence of production of IL-2 at any timepoint after activation (Table 4) .
Steady state messenger R N A (mRNA) levels of IL-2, Tac peptide IL-2 receptor, and y-IFN genes were examined in unactivated PBMC and in PBMC activated for 4, 8, 24, and 48 hours. We did not find expression of IL-2, Tac peptide IL-2 receptor, or y-IFN gene transcripts in unactivated PBMC from any patient. We did not detect IL-2 mRNA in cells from any patients at any time point of activation (Fig 3) . Tac peptide IL-2 mRNA was detected after 48 hours of activation from cells of patient 3 (Fig 3) . Expression of y-IFN gene transcripts was detected in activated cells from all patients Phenotype.
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FLp 2. '%obokd L -2 r . e r q t a o a n p k x n pmducul by 00 proliferative properties of LGL induced by high doses of IL-2 appear to be mediated through this In this study, we found that activation produced by anti-CD3 MoAb resulted in increased numbers of p75 receptors per cell. Activation did not result in expression of high affinity p55-p75 IL-2 receptor complex on leukemic LGL, with one exception: in that case, leukemic LGL were CD4+, unlike the phenotype of the other three cases that were CD8 + . The CD4+ LGL may represent a unique LGL subset with different biologic characteristics than CD8 + LGL. Indeed, normal CD4+ LGL are selectively localized in the germinal centers of lymphoid tissues and do express Tac antigen after anti-CD3 MoAb stimulati~n.~~ It has been suggested that CD3+ LGL may represent in vivo primed CTL with unknown antigen specificity, perhaps against viral-infected targets." In this regard it is of interest that preliminary data suggest that some patients with LGL leukemia may be infected with a retrovirus similar to human T-cell lymphotropic virus-Type I (HTLV-I).40 Similar to the results we observed by adding anti-CD3 MoAb in vitro, viral antigen binding to CD3/TCR complex could result in upregulation of p75 IL-2 binding protein on CD3+ LGL. Upregulation of this intermediate affinity IL-2 receptor might then play an important role in clonal proliferation of these CD3+ LGL in vivo, particularly if additional activation events result in secretion of IL-2.41
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